Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 1;8(4):487-506.
doi: 10.1016/j.ncrna.2023.06.002. eCollection 2023 Dec.

Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review

Meity Ardiana  1   2 , Asiyah Nurul Fadila  1   2 , Zakirah Zuhra  1   2 , Nabilla Merdika Kusuma  3 , Made Edgard Surya Erlangga Rurus  4 , Delvac Oceandy  5
Affiliations
Review

Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review

Meity Ardiana et al. Noncoding RNA Res. .

Abstract

At present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for CVDs and risk factors management. However, data are primarily in an early stage. A systematic review was carried out using literature from several databases (Pubmed, Cochrane, Scopus, and DOAJR) following the PRISMA guidelines. Of the 64 articles reviewed, 39 papers were included in this review with three main types of RNAs: aptamers, antisense oligonucleotides (ASOs), and small-interfering RNA (siRNA). All studies were human clinical trials. RNA-based therapies were demonstrated to be efficacious in treating various CVDs and controlling cardiovascular risk factors. They are generally safe and well-tolerated. However, data are still in the early stage and warrant further investigation.

Keywords: Cardiogenetics; Cardiovascular diseases; Cardiovascular risk factors; Non-coding RNA; RNA therapeutics.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Literature search strategy PRISMA flow diagram.
Fig. 2
Fig. 2
The Mechanism of Actions of ASO, Aptamer and siRNA.
Fig. 3
Fig. 3
ASO, Aptamer, and siRNA in the currently accepted molecular disease model of CVDs and risk factors.
See this image and copyright information in PMC

References

    1. Vaduganathan Muthiah, George A Mensah, Turco Justine Varieur, Valentin Fuster, Roth Gregory A. The global burden of cardiovascular diseases and risk. J. Am. Coll. Cardiol. 2022;80:2361–2371. doi: 10.1016/j.jacc.2022.11.005. - DOI - PubMed
    1. Boada C., Sukhovershin R., Pettigrew R., Cooke J.P. RNA therapeutics for cardiovascular disease. Curr. Opin. Cardiol. 2021;36:256. doi: 10.1097/HCO.0000000000000850. - DOI - PMC - PubMed
    1. Lucas T., Bonauer A., Dimmeler S. RNA therapeutics in cardiovascular disease. Circ. Res. 2018;123:205–220. doi: 10.1161/CIRCRESAHA.117.311311. - DOI - PubMed
    1. Laina A., Gatsiou A., Georgiopoulos G., Stamatelopoulos K., K Stellos. RNA therapeutics in cardiovascular precision medicine. Front. Physiol. 2018;9:953. doi: 10.3389/fphys.2018.00953. - DOI - PMC - PubMed
    1. Quemener A.M., Bachelot L., Forestier A., Donnou-Fournet E., Gilot D., Galibert M.-D. The powerful world of antisense oligonucleotides: from bench to bedside. Wiley Interdiscip Rev RNA. 2020;11:e1594. doi: 10.1002/wrna.1594. - DOI - PMC - PubMed

LinkOut - more resources